Background
==========

The incidence of breast cancer, which can be divided into luminal A, luminal B and triple-negative breast cancer (TNBC) sub-types, ranks the first in female malignant tumors \[[@b1-medscimonit-26-e923507]\]. The cell origin, gene mutation, metastasis potential, disease progression, therapeutic response, and clinical outcome of each subtype are substantially different \[[@b2-medscimonit-26-e923507]\]. TNBC refers to breast cancer with negative estrogen, negative progesterone and negative human epidermal growth factor receptor, and exhibits the worst prognosis \[[@b2-medscimonit-26-e923507]\]. TNBC is prone to recurrence and metastasis, and lacks targeted treatment. Cancer stem cells (CSCs), which contribute to cancer cell progression, play critical effects in recurrence, metastasis, and drug resistance \[[@b3-medscimonit-26-e923507]\]. The proportion of CSCs in TNBC is significantly higher than other subtypes and plenty of evidences indicates that CSCs in TNBC is considered to be a lead factor in its poor prognosis \[[@b3-medscimonit-26-e923507]\]. Thus, targeting CSCs is expected to be an effective means to improve the poor prognosis of TNBC.

LncRNA (long non-coding RNA) is a kind of regulatory non-coding RNA \[[@b4-medscimonit-26-e923507]\]. Its transcript length is more than 200 nt, and it has no obvious open reading frame (ORF) without protein-coding ability \[[@b4-medscimonit-26-e923507]\]. Recently, a large number of studies have shown that lncRNA can modulate gene expression at the transcriptional or post-transcriptional level through binding to DNA, RNA, or protein \[[@b4-medscimonit-26-e923507]\]. With the rapid development of high-throughput sequencing and chip-detection technologies, many kinds of lncRNAs with abnormal expression have been found in breast cancer \[[@b5-medscimonit-26-e923507]\]. Some lncRNAs have been identified to be the important regulators of breast cancer occurrence and development and can be used as effective and accurate indicators for breast cancer diagnosis, for instance, HOTAIR \[[@b6-medscimonit-26-e923507]\], MALAT1 \[[@b7-medscimonit-26-e923507]\], LSINCT5 \[[@b8-medscimonit-26-e923507]\], H19 \[[@b4-medscimonit-26-e923507]\], and BC200 \[[@b9-medscimonit-26-e923507]\], while lncRNA XIST \[[@b10-medscimonit-26-e923507]\] and GAS5 \[[@b11-medscimonit-26-e923507]\] are lowly expressed in breast cancer. HOTAIR expression is positively associated with the poor prognosis of breast cancer \[[@b6-medscimonit-26-e923507]\], and so is MALAT1 expression for breast cancer metastasis \[[@b7-medscimonit-26-e923507]\]. In addition, the abnormal expression of some lncRNAs is closely related to breast cancer occurrence and development. LncRNA HOTAIR promotes breast cancer metastasis of by inhibiting the binding of BRCA1 to EZH2 \[[@b12-medscimonit-26-e923507]\]. H19 increases the proliferation of breast cancer cells by regulating cell cycle through inducing E2F1 and c-Myc expression \[[@b13-medscimonit-26-e923507]\]. LncRNA-NKILA can directly bind to NF-kappa b/I-kappa B, reduce the transcriptional activity of NF-kappa B and thus suppress breast cancer metastasis \[[@b14-medscimonit-26-e923507]\]. LncRNA THOR was initially identified as an ultra-conserved lncRNA in 2017, exhibits an exclusive expression in testis and contributes to tumor growth \[[@b15-medscimonit-26-e923507]\]. Further studies have shown that THOR promotes cell survival and proliferation of osteosarcoma \[[@b16-medscimonit-26-e923507]\], renal cell carcinoma \[[@b17-medscimonit-26-e923507]\], and hepatocellular carcinoma \[[@b18-medscimonit-26-e923507]\]. Notably, recent works showed that THOR enhances the CSC-like traits of gastric cancer cells \[[@b19-medscimonit-26-e923507]\], osteosarcoma cells \[[@b20-medscimonit-26-e923507]\], and liver cancer cells \[[@b21-medscimonit-26-e923507]\]. However, the effects and underlying mechanisms of THOR in breast cancer, especially in TNBC, are unclear.

In our study, THOR expression was determined in luminal A and luminal B breast cancer and TNBC tissues. It was found that THOR was highly expressed in TNBC cells and tissues. Additionally, THOR knockdown reduced TNBC cell stemness through detecting the expression of CSC regulatory factors, ALDH1 activity and sphere-formation ability. Further mechanistic studies revealed that THOR directly interacted with β-catenin messenger RNA (mRNA), enhanced β-catenin mRNA stability and thus increased its expression, which is essential for THOR-induced effects on TNBC cell stemness.

Material and Methods
====================

Clinical samples
----------------

Forty-three pairs of breast tumors (including 15 TNBC sub-types, 17 luminal A sub-types and 11 luminal B sub-types) with adjacent mammary epithelial tissues were obtained from 43 patients who underwent surgery at the Suizhou Hospital Affiliated to Hubei University of Medicine from February 2017 to January 2019 and all cases did not metastasize. Written informed consent has been obtained from each patient. Approval from the Suizhou Hospital Affiliated to Hubei University of Medicine Ethics Committee was obtained for the use of these clinical materials for research purposes. All experiments conform to the Declaration of Helsinki.

Cell culture
------------

Human TNBC lines MDA-MB-453 and MDA-MB-231, luminal B type of breast cancer cell line T-47D, luminal A type of breast cancer cell line MCF-7, and human mammary epithelial cell line MCF-10A cells were purchased from Sino Biological (Beijing, China). RPMI 1640 medium (Thermo Fisher Scientific, Waltham, MA, USA) containing 10% fetal bovine serum (FBS; Biological Industries, Kibbutz Beit Haemek, Israel) was used to culture the cells at 37°C with 5% CO~2~.

Plasmid construction and transfection
-------------------------------------

The short hairpin RNA (shRNA) vector for THOR, overexpression vector for β-catenin and the responding empty vectors were constructed by GENEVIZ (Suzhou, Jiangsu, China), and denoted as THOR-shRNA (5′-CACCGGTCATGACCTGTGCATATG CCGAAGCATATGCACAGGTCATGACC-3′), negative control shRNA (5′-CACCCGACGTGCACCACGTGCTACTCGTACTCTTGATGCC GAGCACGGAA-3′), THOR-oe and β-catenin-oe, respectively. Lipofectamine 3000 (Thermo Fisher Scientific) was used for plasmid transfection according to the instructions. The corresponding empty vector acted as a control.

Real-time quantitative polymerase chain reaction (RT-qPCR)
----------------------------------------------------------

Total RNA was extracted by TRIzol (Tiangen, Beijing, China) and reverse transcribed using Takara reverse transcription kit (Tokyo, Japan). The target genes and control internal reference β-actin were amplified, respectively. The reaction conditions were 95°C for 15 minutes, 94°C for 15 seconds, 60°C for 30 seconds, 72°C for 60 seconds, 40 cycles, 95°C for 15 seconds, 60°C for 15 seconds, and 95°C for 15 seconds to verify the characteristics of the PCR products. Sequence Detector System 2.0 software was used to analyze the data and calculate the genes' relative expressions.

Western blot
------------

ProteinExt^®^ Mammalian Total Protein Extraction Kit (Transgen, Beijing, China) was used to extract the total protein and protein concentration was quantitatively analyzed by BCA kit (Tiangen) as follows: take 1 million cells, discard the culture solution, wash twice with 1 mL precooled phosphate-buffered saline (PBS), centrifugate for 5 minutes at 3000 rpm, and carefully discard the supernatant. The supernatant was collected after centrifugation for 15 minutes. After sodium dodecyl-sulfate polyacrylamide gel electrophoresis (SDS/PAGE), proteins were transferred to the polyvinylidene difluoride (PVDF) membrane (Merck Millipore, Billerica, MA, USA). 5% skimmed-milk powder was used to block the PVDF membrane for 1 hour, then we added the primary antibody: anti-Oct 1: 1000 (Cat\# 11263-1-AP, Proteintech, Wuhan, China); anti-nanog 1: 1000 (Cat\# 14295-1-AP, Proteintech); anti-CD44 1: 1000 (Cat\# 15675-1-AP, Proteintech); anti-β-actin 1: 2000 (Cat\# 60008-1-Ig, Proteintech); anti-β-catenin 1: 1000 (Cat\# 17565-1-AP, Proteintech); anti-Sox9 1: 1000 (Cat\# 67439-1-Ig, Proteintech); anti-c-Myc 1: 1000 (Cat\# 10828-1-AP, Proteintech); anti-Axin2 1: 1000 (Cat\# 20540-1-AP, Proteintech); anti-cyclin D1 1: 1000 (Cat\# 26939-1-AP, Proteintech). Then we incubated at 4°C overnight. After washing, the secondary antibodies were added: HRP-conjugated Affinipure goat anti-mouse IgG(H+L) 1: 5000 (Cat\# SA00001-1, Proteintech); HRP-conjugated Affinipure goat anti-rabbit IgG(H+L) 1: 5000 (Cat\# SA00001-2, Proteintech) and then incubated for 1 hour at room temperature. ECL Plus reagent (Cat\# PE0010, Solarbio, Beijing) was used to expose the membranes. The strips were quantitatively analyzed by GD5800 analysis system.

RNA immunoprecipitation (RIP)
-----------------------------

The interaction between THOR and β-catenin protein was determined using a Magna RIP™ RNA-Binding Protein Immunoprecipitation Kit (Merck Millipore) with anti-β-catenin and control IgG antibody.

RNA-RNA *in vitro* interaction assay
------------------------------------

The detailed procedure was referred to the previous study \[[@b19-medscimonit-26-e923507]\]. Briefly, BrU-labeled RNAs (THOR and THOR-anti-sense) were incubated with beads for another 2 hours at 4°C. Then, β-catenin RNA fragment was added into individual tubes and incubated at 4°C overnight. Subsequently, RNA was extracted from the supernatant after beads were digested using the miRNeasy kit (Qiagen, Duesseldorf), and β-catenin mRNA level was detected by qRT-PCR assay.

mRNA stability analysis
-----------------------

TNBC cells with THOR silencing or not was added with 5 μg/mL actinomycin D (ActD) to terminate transcription. Total RNA was extracted at 0, 2, 4, and 6 hours after adding ActD for quantitative analysis. The β-catenin mRNA half-life (t~l/2~) was measured compared to the mRNA level before adding ActD. The control group was the mRNA from cells treated with responding empty vector.

ALDH1 activity assay
--------------------

ALDH1 activity was evaluated using ALDEFLUOR™ Kit (Cat\# KA3742, Stemcell Technologies) according to the instructions.

Sphere-formation analysis
-------------------------

The cells in logarithmic phase were digested, centrifuged, the medium containing serum was removed, and washed twice with PBS. Then cells were suspended in serum-free DMEM/F12 medium containing 20 ng/mL bFGF (Sigma-Aldrich, St. Louis, MO, USA), 20 ng/mL EGF (Sigma), 20 μL/mL B27 (Sigma) and counted. The cells were cultured in the low adherent 6-well plates with 10^3^ cells/well, and the spheres were calculated after 12 days. In detail, when the diameter of cell sphere was more than 100 μm, spheres size and number were measured and calculated by the confocal laser scanning microscope manually.

Cell viability assay
--------------------

MDA-MB-231 and MDA-MB-435 cells in logarithmic growth period were digested by 0.25% trypsin to make single cell suspension, and the cell concentration was adjusted to 5×10^3^/mL, and repeatedly to make the cells uniform and inoculate them in 96-well culture plates. Cells was added for culture with 5% CO~2~ at 37°C. The concentration of 5 mg/mL MTT solution (Yifeixue, Nanjing, China) was added on day 1, 2, and 3, respectively. The supernatant was removed after incubating at 37°C for 4 hours, and 150 μL dimethyl sulfoxide (DMSO) was added and shaken well to dissolve the crystal for 10 minutes. Then 570 nm was selected and the absorbance (OD) of each well was examined. The relative cell viability was calculated using the formula: cell survival rate=absorbance value of test group/absorbance value of control group×100%.

Statistical analysis
--------------------

SPSS 22.0 software was used for statistical analysis. Results were denoted as the mean±standard deviation), single factor analysis of variance (ANOVA) was used for analysis, and non-paired *t*-test was used for inter-group comparison. *P*\<0.05 was statistically significant.

Results
=======

LncRNA THOR was overexpressed in TNBC
-------------------------------------

THOR expression was initially examined in different sub-types of breast cancer tissues and it was identified that THOR was overexpressed in breast cancer tissues. Especially, THOR displayed the highest level in TNBC tissues ([Figure 1A](#f1-medscimonit-26-e923507){ref-type="fig"}). Additionally, THOR expression was evaluated in normal breast epithelial and different types of breast cancer cells. As shown in [Figure 1B](#f1-medscimonit-26-e923507){ref-type="fig"}, THOR displayed the highest level in TNBC cells and was significantly overexpressed in breast cancer cells. Since the proportion of CSCs is significantly higher in TNBC than that in other sub-types, we assumed that THOR could regulate TNBC cell stemness.

THOR promoted the stemness of TNBC cells
----------------------------------------

We then knocked down THOR expression in TNBC cells to explore its roles as THOR holds the highest level in TNBC cells. The knockdown efficiency was confirmed by RT-qPCR assay ([Figure 2A](#f2-medscimonit-26-e923507){ref-type="fig"}). Notably, it was found that THOR knockdown had no effects on TNBC cell viability ([Figure 2B, 2C](#f2-medscimonit-26-e923507){ref-type="fig"}). Then we determined its effects on TNBC cell stemness. As shown in [Figure 2D--2F](#f2-medscimonit-26-e923507){ref-type="fig"}, the expression of CSC regulatory factors (Oct4, CD44, and Nanog) was decreased by THOR knockdown in TNBC cells. Additionally, ALDH1 activity was reduced by THOR knockdown too ([Figure 2G](#f2-medscimonit-26-e923507){ref-type="fig"}). Moreover, the sphere-formation ability was suppressed by THOR knockdown, as evidenced by decreased sphere size and number ([Figures 2G--2I](#f2-medscimonit-26-e923507){ref-type="fig"}). On the contrary, THOR overexpression significantly increased the stemness of TNBC cells, which was evident as the increased sphere-formation ability and stemness gene expression ([Figure 3](#f3-medscimonit-26-e923507){ref-type="fig"}). These results suggest that THOR could enhance TNBC cell stemness.

THOR directly bound to β-catenin mRNA, enhances its mRNA stability and expression
---------------------------------------------------------------------------------

Then we explored the underlying mechanisms contributing to THOR-mediated effects on TNBC cell stemness. Previous studies have shown that THOR promotes CSC expansion in liver cancer through regulating β-catenin signaling \[[@b21-medscimonit-26-e923507]\], and osteosarcoma by stablizing SOX9 mRNA \[[@b20-medscimonit-26-e923507]\]. Thus, we wonder which signaling pathway was involved, or whether both pathways were involved in THOR-induced effects on TNBC cell stemness. The expression of SOX9 and β-catenin was examined in TNBC cells with THOR silencing or not and it was shown that the expression of β-catenin but not SOX9 was decreased by THOR knockdown ([Figure 4A--4C](#f4-medscimonit-26-e923507){ref-type="fig"}). Therefore, we speculate that THOR may promote TNBC cell stemness at least by activating β-catenin signaling. As lncRNA could directly bind to RNAs or proteins, we initially examined whether THOR physically interacts with β-catenin mRNA using the RNA-RNA *in vitro* interaction assay, and β-catenin protein using RIP assay, it was found that THOR directly bound to β-catenin mRNA but not β-catenin protein ([Figure 4D, 4E](#f4-medscimonit-26-e923507){ref-type="fig"}). Additionally, the mRNA stability assay on β-catenin mRNA showed that THOR knockdown reduced β-catenin mRNA stability, evident by the decrease of β-catenin mRNA half-life ([Figure 4F, 4G](#f4-medscimonit-26-e923507){ref-type="fig"}). Furthermore, the activity of TOP^Flash^ luciferase reporter (a responsive vector of β-catenin) was reduced by THOR knockdown, while the nonresponsive FOP^Flash^ control was unaffected ([Figure 4H](#f4-medscimonit-26-e923507){ref-type="fig"}). In addition, the protein expression of β-catenin and its downstream effectors (c-Myc, AXIN2, and cyclin-D1) was decreased by THOR knockdown in TNBC cells ([Figure 4I](#f4-medscimonit-26-e923507){ref-type="fig"}). Thus, our results demonstrated that THOR could activate β-catenin signaling through directly binding to β-catenin mRNA but not β-catenin protein.

THOR regulated TNBC cell stemness dependent on β-catenin expression
-------------------------------------------------------------------

Finally, we explored whether THOR regulates TNBC cell stemness through β-catenin. β-catenin was overexpressed in TNBC cells with or without THOR knockdown ([Figure 5A, 5B](#f5-medscimonit-26-e923507){ref-type="fig"}). As expected, THOR knockdown-mediated decrease of stemness marker expression was partially reversed by β-catenin overexpression ([Figures 5C--5F](#f5-medscimonit-26-e923507){ref-type="fig"}). Additionally, β-catenin overexpression rescued the reduced ALDH1 activity led by THOR knockdown ([Figure 5G](#f5-medscimonit-26-e923507){ref-type="fig"}). Furthermore, the decreased sphere-formation capacity resulted by THOR silencing was diminished by β-catenin overexpression ([Figure 5H, 5I](#f5-medscimonit-26-e923507){ref-type="fig"}). Collectively, these results indicate that THOR regulated TNBC cell stemness dependent on β-catenin expression.

Discussion
==========

Most of the human genome consists of non-coding sequences, with less than 2% protein-coding genes, which suggests the importance of non-coding RNA in human life \[[@b4-medscimonit-26-e923507]\]. Because of its low expression and poor evolutionary conservativeness, lncRNA was once considered a "transcriptional noise" in chromosomes and neglected \[[@b22-medscimonit-26-e923507]\]. In recent years, with the rapid development of high-throughput sequencing and chip technology, the importance of lncRNA in organisms has gradually been taken seriously. More and more studies have shown that lncRNA plays a role similar to proto-oncogene or anti-oncogene in many malignant tumors. In this study, we focused on THOR roles in TNBC cell stemness since its roles in breast cancer has never been found and it is found at its highest level in TNBC. We found that THOR could not affect TNBC cell proliferation but could significantly attenuate TNBC cell stemness, as evidenced by decreased sphere-formation ability, ALDH1 activity, and CSC regulatory factor expression. To the best of our knowledge, this is the first study showing THOR effects in breast cancer progression.

β-catenin signaling is one of the important pathways in tumor stemness \[[@b23-medscimonit-26-e923507]\]. Previous studies have indicated that THOR exerts its effects on tumor stemness through regulating Sox9 or β-catenin signaling in different tumors individually \[[@b19-medscimonit-26-e923507],[@b20-medscimonit-26-e923507]\]. In the present study, both Sox9 and β-catenin expression were determined in TNBC cells with THOR knockdown and we found that β-catenin expression but not Sox9 expression was decreased by THOR knockdown, which indicates that THOR functions through β-catenin signaling but not Sox9 signaling, and acts through different mechanisms in tumors. Additionally, although the promoting effects of THOR on β-catenin signaling have been confirmed before, the detailed mechanisms by which THOR regulating β-catenin expression is still unclear. THOR has been confirmed to be located in cytoplasm and lncRNA localized in cytoplasm mainly affects gene expression in the following ways: 1) increase the stability of RNA, such as lncRNA-TINCR can stabilize STAU1-RNA through interacting with TINCR box motif of STAU1-RNA. 2) Promote the degradation of STAU1-RNA, such as the lncRNA encoded by 1/2-sbsRNAs can promote the degradation of STAU1-mRNA by binding to the Alu reaction elements in its 3′UTR region \[[@b24-medscimonit-26-e923507]\]. 3) Participate in stress conditions, such as the translocation of antisense lncRNA of Uchl1 from nucleus to cytoplasm, and binds to the 5′end of Uchl1-mRNA to promote the transcription of Uchl1 \[[@b25-medscimonit-26-e923507]\]. 4) Inhibit protein translation by direct interaction with RNA, such as lincRNA-p21 can bind directly to RcK mRNA and inhibit its RcK entering ribosome for protein translation \[[@b26-medscimonit-26-e923507]\]. In the current work, we revealed that THOR could physically interact with β-catenin mRNA through performing *in vitro* RNA-RNA interaction assay and enhance its mRNA stability, while THOR could not interact with β-catenin protein, which indicates that THOR increases β-catenin expression mainly through stabilizing β-catenin mRNA. Notably, as shown in [Figures 4C](#f4-medscimonit-26-e923507){ref-type="fig"} and [5B](#f5-medscimonit-26-e923507){ref-type="fig"}, the mobility shift of β-catenin was also affected by ectopic expression of THOR in TNBC cells. This could be due to the fact that THOR knockdown suppresses the expression of some kinases which can phosphorylate β-catenin, such as AMPK signaling \[[@b27-medscimonit-26-e923507]\], AKT signaling \[[@b18-medscimonit-26-e923507]\], and ERK signaling \[[@b28-medscimonit-26-e923507]\], and thus decreases the phosphorylation level of β-catenin and increases the mobility shift of β-catenin. Other possible reasons that THOR knockdown increases the expression of some splicing factors which could excise β-catenin protein, resulting in an excised β-catenin protein, should be further explored in the future. However, we must admit that the detailed interacted binding sites between THOR and β-catenin mRNA are still unclear, and this should be investigated in the future.

Conclusions
===========

THOR may be a key lncRNA molecule regulating TNBC occurrence and development. Further study on THOR roles in TNBC may provide new ideas for TNBC diagnosis and treatment.
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![LncRNA THOR is overexpressed in TNBC tissues and cells. (**A**) RT-qPCR was used to examine THOR level in different types of breast cancer and adjacent tissues. (**B**) RT-qPCR was conducted to determine THOR level in different types of breast cancer and normal breast epithelial cells. \* *P*\<0.05, \*\* *P*\<0.01. lncRNA -- long non-coding RNA; TBBC -- triple negative breast cancer; RT-q-PCR -- real-time quantitative polymerase chain reaction.](medscimonit-26-e923507-g001){#f1-medscimonit-26-e923507}

![THOR knockdown reduces the stemness of TNBC cells. (**A**) RT-qPCR was constructed to detect the knockdown efficiency of THOR-shRNA in TNBC cells. (**B, C**) The effects of THOR-shRNA on TNBC cell viability. (**D--F**) The mRNA and protein levels of stemness markers were examined in TNBC cells with THOR knockdown or not. (**G**) ALDH1 activity was measured in TNBC cells depicted in (**D**). (**H, I**) The capacity of sphere-formation was evaluated in TNBC cells described in (**D**). \*\* *P*\<0.01. TNBC -- triple negative breast cancer; RT-q-PCR -- real-time quantitative polymerase chain reaction; shRNA -- short hairpin RNA; mRNA -- messenger RNA.](medscimonit-26-e923507-g002){#f2-medscimonit-26-e923507}

![THOR overexpression promotes the stemness of TNBC cells. (**A--C**) The mRNA and protein expression of stemness genes were determined in TNBC cells with THOR overexpression or not. (**D, E**) The sphere size and number were examined in TNBC cells with THOR overexpression or not.\*\* *P*\<0.01. TNBC,-- triple negative breast cancer; mRNA -- messenger RNA.](medscimonit-26-e923507-g003){#f3-medscimonit-26-e923507}

![THOR directly binds to β-catenin mRNA, enhances its mRNA stability and expression. (**A--C**) The mRNA and protein levels of Sox9 and β-catenin were examined in TNBC cells with THOR knockdown or not. (**D**) The *in vitro* RNA-RNA interaction was performed to examine the THOR-β-catenin RNA interaction in TNBC cells. (**E**) RIP assay on THOR level in RNA pulled down by anti-β-catenin. (**F, G**) Analysis on the mRNA stability of β-catenin was performed in TNBC cells with THOR knockdown or not. (**H**) Luciferase reporter analysis on the TOP^flash^ and FOP^flash^ in MDA-MB-453 cells with THOR knockdown or not. (**I**) The expression of the downstream effectors of β-catenin was detected in TNBC cells with THOR knockdown or not. \*\* *P*\<0.01. mRNA -- messenger RNA; TNBC -- triple negative breast cancer; RIP -- RNA immunoprecipitation.](medscimonit-26-e923507-g004){#f4-medscimonit-26-e923507}

![THOR regulates TNBC cell stemness dependent on β-catenin expression. (**A, B**) β-catenin mRNA and protein levels were determined in TNBC cells with THOR knockdown or not, as well as β-catenin overexpression. (**C--F**) The analysis on the expression of stemness markers in the cells denoted in (**B**). (**G**) ALDH1 activity was assessed in the cells denoted in (**B**). (**H, I**) The determination on sphere-formation ability in the cells denoted in (**B**). \*\* *P*\<0.01. TNBC -- triple negative breast cancer; mRNA -- messenger RNA.](medscimonit-26-e923507-g005){#f5-medscimonit-26-e923507}
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